Theriva Biologics, Inc. income statement TOVX

Annual Quarterly

It recorded a net loss of $23.7 million. Diluted earnings per share were -$2.08.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Research and development
5
-49.7%
9
-28.5%
12
-15.9%
14
+22.1%
12
+50.3%
8
+52.0%
5
-53.7%
11
-6.4%
12
-36.9%
19
-35.5%
29
-11.5%
Selling, general and administrative
7
-58.4%
15
+108.9%
7
+3.9%
7
-27.8%
10
+52.3%
6
+28.7%
5
+9.8%
5
-20.0%
6
-23.3%
7
-26.4%
10
+25.6%
Operating income
-12
+60.3%
-24
+8.7%
-26
-22.9%
-21
+0.7%
-22
-51.2%
-14
-40.5%
-10
+35.1%
-16
+10.9%
-18
+33.1%
-26
+33.1%
-39
+4.2%
Interest income
0
-33.0%
0
-58.8%
1
-51.6%
1
+181.1%
1
+8433.3%
0
-86.4%
0
-84.5%
0
+322.4%
0
+219.0%
0
-43.2%
0
+516.7%
Foreign currency gain (loss)
—
0
+725.0%
-0
-233.3%
0
+107.3%
-0
—
—
—
—
—
—
Pretax income
-12
+60.7%
-24
+7.5%
-26
-28.3%
-20
+5.3%
-21
—
—
—
—
—
—
Income tax
—
—
0
+100.0%
-2
-15.1%
-1
0
0
0
0
0
0
Net income
-12
+60.7%
-24
+7.5%
-26
-39.8%
-18
+6.8%
-20
-38.0%
-14
-41.0%
-10
+34.2%
-15
-14.6%
-13
+13.4%
-15
+44.3%
-28
+37.9%
Net income to common
-13
+55.6%
-25
+1.6%
-26
-39.8%
-18
+8.4%
-20
+13.6%
-23
-84.7%
-13
+21.9%
-16
+36.4%
-25
-14.3%
-22
—
Basic EPS
-0.42
+95.2%
-2.08
+89.1%
-19.03
+33.2%
-28.48
-2074.0%
-1.31
+31.1%
-1.90
—
—
—
—
—
Diluted EPS
-0.42
+95.2%
-2.08
+89.1%
-19.03
+33.2%
-28.48
-2074.0%
-1.31
+31.1%
-1.90
—
—
—
—
—
Weighted average shares, basic
31
+833.5%
12
+800.6%
1
+109.2%
1
-95.8%
15
+25.8%
12
—
—
—
—
—
Weighted average shares, diluted
31
+833.5%
12
+800.6%
1
+109.2%
1
-95.8%
15
+25.8%
12
—
—
—
—
—
Other measures
Depreciation and amortization
0
-8.8%
0
-21.2%
0
+1.5%
0
+58.8%
0
-2.3%
0
-56.7%
0
-16.2%
0
-11.8%
0
+11.0%
0
+56.1%
0
+118.1%
EBITDA
-12
+60.5%
-24
+8.6%
-26
-23.1%
-21
+0.9%
-21
-51.5%
-14
-42.5%
-10
+35.4%
-15
+10.8%
-17
+33.5%
-26
+33.5%
-39
+4.4%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TOVX (NYSE)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Rockville, MD
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
894158
Former names
Synthetic Biologics, Inc. (until Oct 12, 2022); ADEONA PHARMACEUTICALS, INC. (until Feb 17, 2012); PIPEX PHARMACEUTICALS, INC. (until Oct 16, 2008); SHEFFIELD PHARMACEUTICALS INC (until Dec 8, 2006); SHEFFIELD MEDICAL TECHNOLOGIES INC (until May 14, 1997)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.